Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cejemly (sugemalimab) is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody, being investigated against locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma.
Lead Product(s): Sugemalimab
Therapeutic Area: Oncology Product Name: Cejemly
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
Cejemly (sugemalimab) is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody, being investigated against metastatic squamous and non-squamous non-small cell lung cancer.
Lead Product(s): Sugemalimab
Therapeutic Area: Oncology Product Name: Cejemly
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Ayvakit (avapritinib) is a kinase inhibitor approved by the FDA for the treatment of adults with Advanced SM, ASM, SM-AHN and MCL, and adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.
Lead Product(s): Avapritinib
Therapeutic Area: Immunology Product Name: Ayvakit
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Gavreto (pralsetinib) is a kinase inhibitor of wild-type RET and oncogenic RET fusions (CCDC6-RET) and mutations. It is approved for adult patients with locally advanced or metastatic RET fusion-positive NSCLC or thyroid cancer and advanced or metastatic RET-mutant MTC.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Cejemly (sugemalimab) is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody, being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.
Lead Product(s): Sugemalimab,Fluorouracil,Cisplatin
Therapeutic Area: Oncology Product Name: Cejemly
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
In the final progression-free survival analysis, CS1001 (sugemalimab) showed sustained clinical benefits in patients with unresectable stage III nSCLC whose disease had not progressed following concurrent or sequential chemoradiotherapy compared with placebo.
Lead Product(s): Sugemalimab
Therapeutic Area: Oncology Product Name: Cejemly
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
The National Medical Products Administration approved Cejemly (sugemalimab) for treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.
Lead Product(s): Sugemalimab
Therapeutic Area: Oncology Product Name: Cejemly
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Results from pre-clinical studies showed that CS5001 exhibited potent and selective cytotoxicity to a variety of ROR1-expressing cancer cell lines and demonstrated remarkable in vivo antitumor activity in both hematological and solid tumor xenograft models.
Lead Product(s): CS5001
Therapeutic Area: Oncology Product Name: CS5001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
CS1003 (nofazinlimab) is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma.
Lead Product(s): Nofazinlimab,Lenvatinib Mesylate
Therapeutic Area: Oncology Product Name: CS1003
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2022
Details:
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region.
Lead Product(s): CS1002,CS1003
Therapeutic Area: Oncology Product Name: CS1002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jiangsu Hengrui Medicine
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 21, 2021